In patients with increased cardiovascular risk, reduction of SBP to <130/80 mm Hg has been shown to reduce CVD complications by 25% and all-cause mortality by 2. After 5 years of randomized therapy in high-CVD-risk patients, ramipril produced a 22% reduction in MI, stroke, or CVD compared with placebo.S9.1-10 No added benefit on CVD outcomes was seen when compared with CCBs and diuretics.S9.1-15,S9.1-16 After 4.2 years of randomized therapy in patients with SIHD, perindopril reduced CVD death, MI, or cardiac arrest by 20% com- pared with placebo.S9.1-7 Beta blockers are effective drugs for preventing angina pectoris, improving exercise time until the onset of angina pectoris, reducing exercise-in- duced ischemic ST-segment depression, and preventing Because of their com- pelling indications for treatment of SIHD, these drugs are recommended as a first-line therapy in the treatment of hypertension when it occurs in patients with SIHD. GDMT beta blockers for SIHD that are also effective in lowering BP include carvedilol, metoprolol tartrate, metoprolol succinate, nadolol, bisoprolol, propranolol, and timolol. Atenolol is not as effective as other antihy- pertensive drugs in the treatment of hypertension.S9.1-23 3. Dihydropyridine CCBs are effective antianginal drugs that can lower BP and relieve angina pectoris when added to beta blockers in patients in whom hyperten- sion is present and angina pectoris persists despite beta- GDMT beta blockers for SIHD that are also effective in low- ering BP include carvedilol, metoprolol tartrate, meto- prolol succinate, nadolol, bisoprolol, propranolol, and timolol. 4. In randomized long-term trials, use of beta blockers af- ter MI reduced all-cause mortality by 23%.S9.1-13 Given the established efficacy of beta blockers for treating hy- pertension and SIHD, their use for treatment continuing beyond 3 years after MI is reasonable.S9.1-6,S9.1-25 5. GDMT beta blockers and CCBs are effective antihyper- tensive and antianginal agents. 